Supplementary Figure 4 Cost-effectiveness acceptability curve. The cost-effectiveness acceptability curve shows the probability that increased FSH dosing based on the AFC is cost-effective compared with a standard FSH regimen, given the observed data, for a range of values of the willingness to pay for an additional live birth. This figure shows that the maximum probability of cost-effectiveness is ~25%.